SCHEMBL708372

SCHEMBL708372

Nc1ccc(/C=C/c2cnc3ccccc3n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAX8 Q06710 1/20 0.56
CYP19A1 P11511 3/20 0.50
MAOA P21397 1/20 0.50
MAOB P27338 1/20 0.50
RAB9A P51151 8/20 0.48
NPC1 O15118 6/20 0.48
MEN1 O00255 4/20 0.46
MAPT P10636 4/20 0.46
KMT2A Q03164 4/20 0.46
CASP3 P42574 1/20 0.46
ATM Q13315 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
GRM4 Q14833 3/20 0.46
KDM4E B2RXH2 6/20 0.45
LMNA P02545 3/20 0.45
PKM P14618 1/20 0.45
ALDH1A1 P00352 4/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL708373 1.00 PAX8 (0.56) PAX8CYP19A1MAOAMAOBRAB9A
SCHEMBL12923109 0.91 PAX8 (0.63) PAX8RAB9ANPC1MEN1MAPT
SCHEMBL711461 0.86 KDM4E (0.59) PAX8RAB9ANPC1MEN1MAPT
SCHEMBL711460 0.86 KDM4E (0.59) PAX8RAB9ANPC1MEN1MAPT
SCHEMBL708683 0.83 PAX8 (0.56) PAX8RAB9ANPC1MEN1MAPT
SCHEMBL712709 0.83 RAB9A (0.64) PAX8RAB9ANPC1MEN1MAPT
SCHEMBL710216 0.83 PAX8 (0.56) PAX8RAB9ANPC1MEN1MAPT
SCHEMBL714074 0.83 PAX8 (0.56) PAX8RAB9ANPC1MEN1MAPT
SCHEMBL714075 0.83 PAX8 (0.56) PAX8RAB9ANPC1MEN1MAPT
SCHEMBL708682 0.83 PAX8 (0.56) PAX8RAB9ANPC1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20040242615-A1 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242615-A1 Utilities of olefin derivatives APOL1, NR1H2, APOB PAX8 4417/4885CYP19A1 150/4885MAOA 353/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 PAX8 4618/4885CYP19A1 295/4885MAOA 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.